Patients with the inflammatory bowel disease ulcerative colitis have a higher risk of dying from colorectal cancer, despite modern therapy, even though the risk has declined in recent years. Olén et al published these findings in The Lancet.
Previous research has shown that patients with ulcerative colitis have an increased risk of colorectal cancer, and therefore, screening recommendations are in place for this patient group. But to what extent have new therapeutic methods helped to reduce risk? This much-debated question has now found new answers. A large study involving 96,000 patients diagnosed with ulcerative colitis between the years 1969 and 2017 has shown that these patients run a higher risk of developing and dying of colorectal cancer.
“The risk of colorectal cancer has dropped substantially over the past 30 years, but in spite of this, patients who have had access to modern treatments for ulcerative colitis and screening for colorectal cancer still have a significantly elevated risk,” said Ola Olén, MD, senior researcher in the Department of Medicine in Solna at the Karolinska Institutet in Sweden.
Over the entire study period (1969–2017), the chances of a patient with ulcerative colitis being diagnosed with colorectal cancer were 66% higher than the control group, with the corresponding mortality rate being 59% higher. For the latest 5-year period only, however, these figures were, respectively, 38% and 25%.
This study differs from previous ones in that it factored in both the tumor stage when the cancer risk was assessed and the mortality rates, which the researchers included to ensure that the risks were not being overestimated. The reason for examining mortality from colorectal cancer and not only incidence for this cancer is that regular endoscopic screening might detect relatively early forms of colorectal cancer that would otherwise go undetected.
“An important result of the study is that the risks are indeed elevated, but there are major differences from one patient group to another,” said Dr. Olén. At particularly high risk of developing colorectal cancer are patients with extensive colitis, primary sclerosing cholangitis, heredity for colorectal cancer susceptibility, or childhood-onset ulcerative colitis.
According to study coauthor Jonas F. Ludvigsson, MD, at the Department of Medical Epidemiology and Biostatistics at the Karolinska Institutet, the study indicates a need to develop the care provided for these patients even further. “Our study shows that screening and treatment of these patients can likely be further improved, since patients with ulcerative colitis are still more likely to die of colon cancer,” he concluded.
Disclosure: For full disclosures of the study authors, visit thelancet.com.The content in this post has not been reviewed by the American Society of Clinical Oncology, Inc. (ASCO®) and does not necessarily reflect the ideas and opinions of ASCO®.